Documente Academic
Documente Profesional
Documente Cultură
Aplazia eritrocitară pură (AEP) determinată de 9. Harper P, Littlewood T. Anaemia of cancer: impact on patient fatigue
anticorpii neutralizanţi antieritropoietină a fost observată în and longterm outcome. Oncology 2005; 69 (Suppl 2): 2–7.
10. Ryan JL, Carroll JK, Ryan EP et al. Mechanisms of cancer-related
asociere cu ESA în cazul pacienţilor cu insuficienţă renală fatigue. Oncologist 2007; 12 (Suppl 1): 22–34.
cronică [V], deşi nu au fost raportate cazuri de AEP la 11. Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent
pacienţii cu cancer. Probabil că aceasta a fost determinată prognostic factor for survival in patients with cancer: a systematic,
de probleme de fabricaţie [II, B]. quantitative review. Cancer 2001; 91: 2214–2221.
12. http://www.emea.europa.eu/humandocs/Humans/EPAR (last
Alte reacţii adverse ale ESA sunt reacţii alergice accessed 17 March 2008).
rare care au inclus dispnee, erupţie cutanată şi urticarie; 13. Bohlius J, Wilson J, Seidenfeld J et al. Erythropoetin or darbepoetin
artralgii; edeme periferice; şi durere uşoară şi tranzitorie la for patients with cancer. Cochrane Database Syst Rev 2006; issue 3:
locul injectării [I]. CD003407.
14. Glaspy JA. Erythropoietin in cancer patients. Annu Rev Med 2009;
60: 181–192.
Consideraţii farmaco-economice 15. Casadevall N, Durieux P, Dubois S et al. Health, economic, and
Utilizarea ESA creşte semnificativ costurile asociate quality-of-life effects of erythropoietin and granulocyte colony-
stimulating factor for the treatment of myelodysplastic syndromes: a
îngrijirii sănătăţii [I], iar costul per an de viaţă ajustat în randomized, controlled trial. Blood 2004; 104: 321–327.
funcţie de calitate (QALY, quality-adjusted life-year) este 16. Italian Cooperative Study Group for rHuEpo in Myelodysplastic
estimat la 208 000 € deoarece nu pare a exista un beneficiu Syndromes. A randomized double-blind placebo-controlled study
în privinţa supravieţuirii [II]. with subcutaneous recombinant human erythropoietin in patients
with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103:
Notă 1070–1074.
17. Ross SD, Allen IE, Probst CA et al. Efficacy and safety of
În parantezele pătrate sunt prezentate nivelurile de erythropoiesisstimulating proteins in myelodysplastic syndrome:
a systematic review and metaanalysis. Oncologist 2007; 12: 1264–
evidenţă [I–V] şi gradele de recomandare [A–D] utilizate 1273.
de American Society of Clinical Oncology. Afirmaţiile fără 18. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the
grade alocate au fost considerate practica clinică standard response to recombinant human erythropoietin in cancer patients with
de către autori şi comitetul ESMO. chemotherapy-related anemia: a multicenter, open-label, randomized
trial. J Clin Oncol 2004; 22: 1301–1307.
Bibliografie 19. Bastit L, Vandebroek A, Altintas S et al. Randomized, multicenter,
controlled trial comparing the efficacy and safety of darbepoetin
1. Blanc B, Finch CA, Hallberg L et al. Nutritional anaemias. Report of alpha administered every 3 weeks with or without intravenous iron in
a WHO Scientific Group. WHO Tech Rep Ser 1968; 405: 1–40. patients with chemotherapy-induced anemia. J Clin Oncol 2008; 26:
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: 1611–1618.
incidence and treatment. J Natl Cancer Inst 1999; 91: 1616–1634. 20. Smith RE, Aapro M, Ludwig H et al. Darbepoetin alfa for the
3. Mercadante S, Gebbia V, Marrazzo A et al. Anemia in cancer: treatment of anemia in patients with active cancer not receiving
pathophysiology and treatment. Cancer Treat Rev 2000; 26: 303–311. chemotherapy or radiotherapy: results of a phase III, multicenter,
4. Wilson J, Yao GL, Raftery J et al. A systematic review and economic randomized, double-blind, placebo-controlled study. J Clin Oncol
evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in 2008; 26: 1040–1050.
anaemia associated with cancer, especially that attributable to cancer 21. Ludwig H, Crawford J, Osterborg A et al. Pooled analysis of
treatment. Health Technol Assess 2007; 11: 1–202. individual patientlevel data from all randomized, double-blind,
5. Ludwig H, Van Belle S, Barrett-Lee et al. The European Cancer placebo-controlled trials of darbepoetin alfa in the treatment of
Anaemia Survey (ECAS): a large, multinational, prospective survey patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27:
defining the prevalence, incidence, and treatment of anaemia in 2838–2847.
cancer patients. Eur J Cancer 2004; 40: 2293–2306. 22. Bohlius J, Schmidlin K, Brillant C et al. Recombinant human
6. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell erythropoiesis-stimulating agents and mortality in patients with
transfusions and iron overload in the treatment of patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373:
myelodysplastic syndromes. Cancer 2008; 112: 1089–1095. 1532–1542. Erratum in Lancet 2009; 374: 28.
7. Birgegård G, Gascón P, Ludwig H. Evaluation of anaemia in patients 23. Tonelli M, Hemmelgarn B, Reiman T et al. Benefits and harms of
with multiple myeloma and lymphoma: findings of the European erythropoiesisstimulating agents for anemia related to cancer: a meta-
Cander Anaemia Survey. Eur J Haematol 2006; 77: 378–386. analysis. CMAJ 2009; 180: E62–E71.
8. http://ctep.info.nih.gov/reporting/ctc_archive.html (last accessed 8 24. Bennett CL, Luminari S, Nissenson AR et al. Pure red cell aplasia and
May 2009). epoetin therapy. N Engl J Med 2004; 351: 1403–1408.